- Home
- QSI vs JBIO Comparison
QSI vs JBIO Comparison
Compare QSI & JBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- JBIO
- Stock Information
- Founded
- QSI 2013
- JBIO 2024
- Country
- QSI United States
- JBIO United States
- Employees
- QSI N/A
- JBIO N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- JBIO
- Sector
- QSI Health Care
- JBIO
- Exchange
- QSI Nasdaq
- JBIO NYSE
- Market Cap
- QSI 334.9M
- JBIO 290.1M
- IPO Year
- QSI N/A
- JBIO N/A
- Fundamental
- Price
- QSI $1.93
- JBIO $8.28
- Analyst Decision
- QSI Strong Buy
- JBIO Strong Buy
- Analyst Count
- QSI 3
- JBIO 2
- Target Price
- QSI $2.38
- JBIO $15.50
- AVG Volume (30 Days)
- QSI 8.0M
- JBIO 397.1K
- Earning Date
- QSI 08-05-2025
- JBIO 08-05-2025
- Dividend Yield
- QSI N/A
- JBIO N/A
- EPS Growth
- QSI N/A
- JBIO N/A
- EPS
- QSI N/A
- JBIO N/A
- Revenue
- QSI $3,443,000.00
- JBIO N/A
- Revenue This Year
- QSI $77.57
- JBIO N/A
- Revenue Next Year
- QSI $251.34
- JBIO N/A
- P/E Ratio
- QSI N/A
- JBIO N/A
- Revenue Growth
- QSI 167.94
- JBIO N/A
- 52 Week Low
- QSI $0.61
- JBIO $1.61
- 52 Week High
- QSI $5.77
- JBIO $13.50
- Technical
- Relative Strength Index (RSI)
- QSI 56.01
- JBIO N/A
- Support Level
- QSI $1.68
- JBIO N/A
- Resistance Level
- QSI $1.99
- JBIO N/A
- Average True Range (ATR)
- QSI 0.11
- JBIO 0.00
- MACD
- QSI 0.01
- JBIO 0.00
- Stochastic Oscillator
- QSI 81.25
- JBIO 0.00
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About JBIO JADE BIOSCIENCES INC
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.